Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037487 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Smoked THC and CBD in Men and Women
A Phase 1 study of Drug Abuse and Impairment, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT05037487: Completed Phase 1 study of Drug Abuse and Impairment, sponsored by University of California, Los Angeles.
NCT05037487 is a Phase 1 study of Drug Abuse and Impairment that has completed, run by University of California, Los Angeles. The registered enrollment target is 19 participants, below the 325-participant average among 21 other Drug Abuse trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05037487, a Phase 1 study of Drug Abuse and Impairment, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
Primary Outcome
Peak subjective ratings of drug effects associated with abuse liability and impairment as measured using visual analogue scales (VAS; 1-100mm).
Conditions Studied
Interventions
- DRUG Placebo Cannabis
- DRUG 20 mg CBD Cannabis
- DRUG 20 mg CBD + 20 mg THC Cannabis
- DRUG 20 mg THC Cannabis
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2025-06-08 |
| Phase | Phase 1 |
What the finished NCT05037487 record still lists
NCT05037487 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 325-participant average among 21 other Drug Abuse trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Drug Abuse appearing as the primary indexed condition, and to 4 interventions - of which Placebo Cannabis is the first listed.
NCT05037487 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05037487 about?
NCT05037487 is a clinical study titled "Evaluation of Smoked THC and CBD in Men and Women". The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
What is the current status of trial NCT05037487?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-09-01. Estimated completion is 2025-06-08.
What conditions does trial NCT05037487 study?
This clinical trial studies the following conditions: Drug Abuse, Impairment, Intoxication by Drug.
What interventions are being tested in trial NCT05037487?
The interventions under investigation include: Placebo Cannabis (DRUG), 20 mg CBD Cannabis (DRUG), 20 mg CBD + 20 mg THC Cannabis (DRUG), 20 mg THC Cannabis (DRUG).
Who is sponsoring clinical trial NCT05037487?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05037487 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05037487's enrollment target sits among peer trials
19 22nd of 21 the lowest of 21 other Drug Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Drug Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Abuse Potential of Istradefylline
COMPLETED · Phase 1
-
Acute Intervention to Reduce Distress Following Sexual Assault
COMPLETED · Phase 1
-
Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use
COMPLETED · Phase 1
-
Disulfiram Interactions With HIV Medications: Clinical Implications
COMPLETED · Phase 1
-
Wakaya: Rising Up for Choctaw Youth Health
RECRUITING · NA
-
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI